Oxford University Innovation Ltd

Isis Innovation Limited

R.p.scherer Technologies, Inc.

Psioxus Therapeutics Limited

Benjamin Guy Davis

Daniel Clive Anthony

Nicola Ruth Sibson

Francis Joseph Carr

Timothy David Jones

Hagan Bayley

Kerry David Fisher

Leonard William Seymour

David Philip Gamblin

Antony John Fairbanks

Philippe Garnier

Thomas Taylor

Matthew J Paul

Guillaume Bort

Sandra Jane Campbell

Thomas B Parsons

Jonathan Goodfellow

Keisuke Yamamoto

Lingbing Kong

Filip Wyszynski

Goncalo Bernardes

Robin Patrick Choudhury

Justin Chalker

Ram Sagar

Hua Wang

Lucia F Primavesi

Sander Izaak Van Kasteren

Described herein are antibody conjugates and methods of making antibody conjugates.

Antibody conjugates and methods of making the antibody conjugates

The invention relates to tunicamycin analogues which are compounds according to Formula (I), or pharmaceutically acceptable salts thereof, (I) Wherein [Base] and Rto Rare as defined herein. The tunicamycin analogues are useful in the prevention or treatment of bacterial infection, in particular of tuberculosis. 

Tunicamycin analogues

The invention provides an antibody or fragment thereof that specifically binds to human endothelial vascular cell adhesion molecule-1 (VCAM-1), wherein the antibody or fragment thereof binds to the extracellular domain of VCAM-1, and wherein the antibody or fragment thereof binds to VCAM-1 when expressed on endothelial cells, wherein the antibody or fragment thereof is a human or humanized antibody, or fragment thereof.

Antibodies against CD106 (VCAM-1)

An imaging agent comprising a conjugate of an oligosaccharide moiety with an imaging moiety. The oligosaccharide is Lewis A or Lewis B or a mimetic thereof, or a pharmaceutically acceptable salt or PEGylated form of Lewis A or Lewis B or its mimetics. Lewis A and Lewis B and its mimetics are also provided for use in the therapeutic treatment of inflammatory diseases, autoimmune diseases and cancer.

Inflammation imaging and therapy

Compounds which inhibit Wza-mcdiated polysaccharide transport are useful in the prevention or treatment of bacterial infection, in particular ofinfection. The compounds are typically cyclic oligosaccharides such as cyclodextrins, which bear positively charged functional groups at the primary carbon position.

Cyclic oligosaccharides for use in the treatment and prevention of bacterial infection

The invention relates to methods for selectively converting a cysteine residue in a peptide or protein to the dehydroalanine (Dha) residue. The method also works on selenocysteine and substituted cysteine and selenocysteine residues, resulting in the Dha residue which may be converted to any natural or unnatural amino acid residue desired without the alteration of the remainder of the peptide or protein. The invention also allows ligation of a desired peptide at any point rather than at a point where there should be a naturally occurring cysteine, thereby allowing native chemical ligation to be used in the synthesis of peptides that do not contain cysteine. The methodology allows for the synthesis of very large peptides.

Chemical modification of proteins

Compounds which are trehalose-6-phosphate or trehalose-6-phosphonate precursors of formula (I) or agriculturally acceptable salts thereof are provided: (I) The compounds are useful in increasing starch production in plants. 

Modification of trehalose-6-phosphate levels in plants

The invention provides multimeric particle comprising metal-containing particles covalently bonded to one another by linker groups wherein at least some of said linker groups are cleavable. The invention further provides a contrast agent comprising said multimeric particles, along with a method of improving contrast of an image using said contrast agent.

Multimeric particles

Modified viral particles wherein the viral particles, typically adenoviral particles, are modified by glycosylation and the use of the modified viral particles to deliver heterologous nucleic acid to cells. Also disclosed are pharmaceutical compositions comprising the same and method of treatment using the same.

Modified virus

Methods and reagents for the formation of disulfide bonds, particularly in proteins, peptides and amino acids. The methods and reagents are particularly useful for the controlled glycosylation of proteins, peptides and amino acids. The methods utilize thiosulfonate or selenenylsulfide compounds as reagents or intermediates. Some proteins and peptides comprising selenenyl-sulfide groups also form part of the invention.

Reagents and methods for the formation of disulfide bonds and the glycosylation of proteins

A modified polypeptide having carbohydrate processing enzymatic activity is provided, said polypeptide comprising an amino acid sequence selected from: (a) the amino acid sequence of SEQ ID NO:2 comprising a mutation in at least one of W433, E432 and M439; (b) the amino acid sequence of an enzyme of glycosyl hydrolase family 1, comprising at least one mutation at an amino acid residue equivalent to W433, E432 or M439 of SEQ ID NO:2; and (c) a variant of (a) or (b) having carbohydrate processing enzymatic activity and comprising at least one amino acid mutation at a position equivalent to W433, E432 or M439 of SEQ ID NO:2.

Growing community of inventors

Oxford, United Kingdom

Benjamin Guy Davis